KOBV Portal

Hits per page

hits 1 - 10 | 103 hits

Sorting

Online Resource

Modular transcriptional repertoire analyses identify a blood neutrophil signature as a candidate biomarker for lupus nephritis

Jourde-Chiche, Noémie ; Whalen, Elizabeth ; Gondouin, Bertrand ; [et al.]

Oxford University Press (OUP) ; 2016

In: Rheumatology

add to watchlist on the watchlist

Details

In: Rheumatology, Oxford University Press (OUP)

Type of Medium: Online Resource

ISSN: 1462-0324 , 1462-0332

URL: Article

DOI: 10.1093/rheumatology/kew439

Language: English

Publisher: Oxford University Press (OUP)

Publication Date: 2016

detail.hit.zdb_id: 1474143-X

Bookmarklink

Library	Location	Call Number	Volume/Issue/Year	Availability

Others were also interested in ...

Online Resource

Open Access Request

Availability (electronic / print)

Link to publisher

Online Resource

Characterization of regulatory T cells in obese omental adipose tissue in humans

Wu, Dan ; Han, Jonathan M. ; Yu, Xin ; [et al.]

Wiley ; 2019

In: European Journal of Immunology Vol. 49, No. 2 ( 2019-02), p. 336-347

add to watchlist on the watchlist

Details

In: European Journal of Immunology, Wiley, Vol. 49, No. 2 ( 2019-02), p. 336-347

Abstract: Obesity‐associated visceral adipose tissue (AT) inflammation promotes insulin resistance and type 2 diabetes (T2D). In mice, lean visceral AT is populated with anti‐inflammatory cells, notably regulatory T cells (Tregs) expressing the IL‐33 receptor ST2. Conversely, obese AT contains fewer Tregs and more proinflammatory cells. In humans, however, there is limited evidence for a similar pattern of obesity‐associated immunomodulation. We used flow cytometry and mRNA quantification to characterize human omental AT in 29 obese subjects, 18 of whom had T2D. Patients with T2D had increased proportions of inflammatory cells, including M1 macrophages, with positive correlations to body mass index. In contrast, Treg frequencies negatively correlated to body mass index but were comparable between T2D and non‐T2D individuals. Compared to human thymic Tregs, omental AT Tregs expressed similar levels of FOXP3, CD25, IKZF2 , and CTLA4 , but higher levels of PPARG , CCR4 , PRDM1 , and CXCL2 . ST2, however, was not detectable on omental AT Tregs from lean or obese subjects. This is the first comprehensive investigation into how omental AT immunity changes with obesity and T2D in humans, revealing important similarities and differences to paradigms in mice. These data increase our understanding of how pathways of immune regulation could be targeted to ameliorate AT inflammation in humans.

Type of Medium: Online Resource

ISSN: 0014-2980 , 1521-4141

URL: Issue

URL: Article

DOI: 10.1002/eji.v49.2

DOI: 10.1002/eji.201847570

RVK:

XA 10000

Language: English

Publisher: Wiley

Publication Date: 2019

detail.hit.zdb_id: 1491907-2

Bookmarklink

Library	Location	Call Number	Volume/Issue/Year	Availability

Others were also interested in ...

Online Resource

Open Access Request

Availability (electronic / print)

Link to publisher

Online Resource

Attenuated IL-2R signaling in CD4 memory T cells of T1D subjects is intrinsic and dependent on activation state

Schwedhelm, Katharine ; Thorpe, Jerill ; Murray, Sara A. ; [et al.]

Elsevier BV ; 2017

In: Clinical Immunology Vol. 181 ( 2017-08), p. 67-74

add to watchlist on the watchlist

Details

In: Clinical Immunology, Elsevier BV, Vol. 181 ( 2017-08), p. 67-74

Type of Medium: Online Resource

ISSN: 1521-6616

URL: Article

DOI: 10.1016/j.clim.2017.06.004

RVK:

XA 36852

Language: English

Publisher: Elsevier BV

Publication Date: 2017

detail.hit.zdb_id: 1462862-4

Bookmarklink

Library	Location	Call Number	Volume/Issue/Year	Availability

Others were also interested in ...

Online Resource

Open Access Request

Availability (electronic / print)

Link to publisher

Online Resource

Characterization of CD4+ T cells expressing an elevated interferon-stimulated gene signature in SLE patients

Murray, Sara ; Speake, Cate ; Mason, Michael J ; [et al.]

The American Association of Immunologists ; 2016

In: The Journal of Immunology Vol. 196, No. 1_Supplement ( 2016-05-01), p. 124.19-124.19

add to watchlist on the watchlist

Details

In: The Journal of Immunology, The American Association of Immunologists, Vol. 196, No. 1_Supplement ( 2016-05-01), p. 124.19-124.19

Abstract: The type I interferon (IFN) signaling pathway plays a key role in Systemic Lupus Erythematosus (SLE) pathology, and a majority of patients display elevated expression levels of interferon-stimulated genes (ISGs) in the peripheral blood. However, it is unclear which immune cells are responding to IFN to drive disease pathology. We compared the ISG signatures of cell types sorted from peripheral blood of IFNβ-treated relapsing-remitting multiple sclerosis (RRMS) patients with those of SLE patients. While systemic IFNβ treatment stimulated ISG expression in the monocytes and neutrophils of RRMS patients, the ISG signature in SLE patients was primarily detected in CD4+ T and B cells. This suggests these cells may be exposed to higher levels of IFN in microenvironments of inflammation within SLE patients, such as upon interaction with APC presenting SLE antigens. We hypothesize that a subset of primarily antigen-specific CD4+ T cells expand and express ISGs during SLE disease activity, and that these cells and their signature pathways can serve as disease biomarkers and therapeutic targets. To examine ISG expression by CD4+ T cells in SLE, we compared the expression of several ISG-correlated surface markers between high- and low-IFN score patients and healthy controls. Subsets of CD4+ T cells in high-IFN score patients expressed elevated levels of PD1, CD66a, and OX40, while the majority of cells expressed a similar level as cells in healthy controls. This suggests that only a small subset of CD4+ T cells is activated by localized IFN sources and is involved in SLE pathology. We have further characterized PD1+, OX40+ CD66a+, and SLE-specific memory CD4+ T cells by RNAseq and flow cytometry.

Type of Medium: Online Resource

ISSN: 0022-1767 , 1550-6606

URL: Article

DOI: 10.4049/jimmunol.196.Supp.124.19

RVK:

XA 54100

RVK:

XA 10000

Language: English

Publisher: The American Association of Immunologists

Publication Date: 2016

detail.hit.zdb_id: 1475085-5

Bookmarklink

Library	Location	Call Number	Volume/Issue/Year	Availability

Others were also interested in ...

Online Resource

Open Access Request

Availability (electronic / print)

Link to publisher

Online Resource

Abnormalities in proinsulin processing in islets from individuals with longstanding T1D

Sims, Emily K. ; Syed, Farooq ; Nyalwidhe, Julius ; [et al.]

Elsevier BV ; 2019

In: Translational Research Vol. 213 ( 2019-11), p. 90-99

add to watchlist on the watchlist

Details

In: Translational Research, Elsevier BV, Vol. 213 ( 2019-11), p. 90-99

Type of Medium: Online Resource

ISSN: 1931-5244

URL: Article

DOI: 10.1016/j.trsl.2019.08.001

Language: English

Publisher: Elsevier BV

Publication Date: 2019

detail.hit.zdb_id: 2252085-5

Bookmarklink

Library	Location	Call Number	Volume/Issue/Year	Availability

Others were also interested in ...

Online Resource

Open Access Request

Availability (electronic / print)

Link to publisher

Online Resource

Strength in Numbers: Opportunities for Enhancing the Development of Effective Treatments for Type 1 Diabetes—The TrialNet Experience

Greenbaum, Carla J. ; Speake, Cate ; Krischer, Jeffrey ; [et al.]

American Diabetes Association ; 2018

In: Diabetes Vol. 67, No. 7 ( 2018-07-01), p. 1216-1225

add to watchlist on the watchlist

Details

In: Diabetes, American Diabetes Association, Vol. 67, No. 7 ( 2018-07-01), p. 1216-1225

Abstract: The early to mid-1980s were an inflection point in the history of type 1 diabetes research. Two landmark events occurred: the initiation of immune-based interventions seeking to prevent type 1 diabetes and the presentation of an innovative model describing the disorder’s natural history. Both formed the basis for hundreds of subsequent studies designed to achieve a dramatic therapeutic goal—a means to prevent and/or reverse type 1 diabetes. However, the need to screen large numbers of individuals and prospectively monitor them using immunologic and metabolic tests for extended periods of time suggested such efforts would require a large collaborative network. Hence, the National Institutes of Health formed the landmark Diabetes Prevention Trial-Type 1 (DPT-1) in the mid-1990s, an effort that led to Type 1 Diabetes TrialNet. TrialNet studies have helped identify novel biomarkers; delineate type 1 diabetes progression, resulting in identification of highly predictable stages defined by the accumulation of autoantibodies (stage 1), dysglycemia (stage 2), and disease meeting clinical criteria for diagnosis (stage 3); and oversee numerous clinical trials aimed at preventing disease progression. Such efforts pave the way for stage-specific intervention trials with improved hope that a means to effectively disrupt the disorder’s development will be identified.

Type of Medium: Online Resource

ISSN: 0012-1797 , 1939-327X

URL: Article

DOI: 10.2337/db18-0065

Language: English

Publisher: American Diabetes Association

Publication Date: 2018

detail.hit.zdb_id: 1501252-9

Bookmarklink

Library	Location	Call Number	Volume/Issue/Year	Availability

Others were also interested in ...

Online Resource

Open Access Request

Availability (electronic / print)

Link to publisher

Online Resource

Autoantibody Reversion: Changing Risk Categories in Multiple-Autoantibody–Positive Individuals

So, Michelle ; O’Rourke, Colin ; Bahnson, Henry T. ; [et al.]

American Diabetes Association ; 2020

In: Diabetes Care Vol. 43, No. 4 ( 2020-04-01), p. 913-917

add to watchlist on the watchlist

Details

In: Diabetes Care, American Diabetes Association, Vol. 43, No. 4 ( 2020-04-01), p. 913-917

Abstract: Most individuals with two or more islet autoantibodies progress to clinical type 1 diabetes. However, in some individuals, autoantibodies are subsequently lost. Here, our objectives were to determine the frequency of autoantibody loss (reversion) in multiple-autoantibody–positive individuals and to determine the association between reversion and progression to clinical disease. RESEARCH DESIGN AND METHODS We analyzed multiple-autoantibody–positive individuals participating in TrialNet’s Pathway to Prevention Study for reversion and determined the effect of reversion on progression to clinical disease using a Cox regression analysis. RESULTS Of 3,284 multiple-autoantibody–positive subjects, reversion occurred in 134 (4.1%) and was associated with reduced incidence of clinical disease. Reversion occurred more frequently with older age, lower autoantibody titers, and fewer positive autoantibodies. CONCLUSIONS Although reversion of multiple-autoantibody positivity is rare, when it occurs, the risk of progressing to clinical disease is reduced. This suggests unknown mechanisms promoting immune remission in some individuals.

Type of Medium: Online Resource

ISSN: 0149-5992 , 1935-5548

URL: Article

DOI: 10.2337/dc19-1731

Language: English

Publisher: American Diabetes Association

Publication Date: 2020

detail.hit.zdb_id: 1490520-6

Bookmarklink

Library	Location	Call Number	Volume/Issue/Year	Availability

Others were also interested in ...

Online Resource

Open Access Request

Availability (electronic / print)

Link to publisher

Online Resource

87-OR: Disappearing Antibodies: Frequency and Effect on T1D Progression

O'ROURKE, COLIN ; SO, MICHELLE ; GREENBAUM, CARLA ; [et al.]

American Diabetes Association ; 2019

In: Diabetes Vol. 68, No. Supplement_1 ( 2019-06-01)

add to watchlist on the watchlist

Details

In: Diabetes, American Diabetes Association, Vol. 68, No. Supplement_1 ( 2019-06-01)

Abstract: While the majority of individuals with ≥2 autoantibodies (AAB) will progress to clinical T1D, there are reports that AAB disappear in some individuals. Clinical trials to delay or prevent disease progression often enroll those at stage 1 or 2, defined as individuals with ≥2 AAB confirmed on two separate occasions. Using data from TrialNet’s Pathway to Prevention study, we aimed to determine (a) how many individuals at stage 1 or 2 subsequently lost AAB, and (b) how this impacted the risk of T1D progression. Individuals confirmed to be at stage 1 or stage 2 diabetes with a mean follow-up of 2.2 years (0.1 to 13) were included (n=3267). 3141 (96%) maintained their status over time while 126 (4%) did not (non-maintainers). This affected their risk of progression (Figure). Conclusion: Reverting from stage 1 or stage 2 diabetes is rare; yet, if it occurs, the risk of progressing to stage 3 during the follow-up period is reduced. This suggests that there are unknown mechanisms that can lead to immune remission in some individuals. Disclosure C. O'Rourke: None. M. So: None. C. Greenbaum: Research Support; Self; Janssen Research & Development. H.T. Bahnson: None. C. Speake: None. Funding JDRF; National Institutes of Health

Type of Medium: Online Resource

ISSN: 0012-1797 , 1939-327X

URL: Article

DOI: 10.2337/db19-87-OR

Language: English

Publisher: American Diabetes Association

Publication Date: 2019

detail.hit.zdb_id: 1501252-9

Bookmarklink

Library	Location	Call Number	Volume/Issue/Year	Availability

Others were also interested in ...

Online Resource

Open Access Request

Availability (electronic / print)

Link to publisher

Online Resource

Standardizing T-Cell Biomarkers in Type 1 Diabetes: Challenges and Recent Advances

Ahmed, Simi ; Cerosaletti, Karen ; James, Eddie ; [et al.]

American Diabetes Association ; 2019

In: Diabetes Vol. 68, No. 7 ( 2019-07-01), p. 1366-1379

add to watchlist on the watchlist

Details

In: Diabetes, American Diabetes Association, Vol. 68, No. 7 ( 2019-07-01), p. 1366-1379

Abstract: Type 1 diabetes (T1D) results from the progressive destruction of pancreatic β-cells in a process mediated primarily by T lymphocytes. The T1D research community has made dramatic progress in understanding the genetic basis of the disease as well as in the development of standardized autoantibody assays that inform both disease risk and progression. Despite these advances, there remains a paucity of robust and accepted biomarkers that can effectively inform on the activity of T cells during the natural history of the disease or in response to treatment. In this article, we discuss biomarker development and validation efforts for evaluation of T-cell responses in patients with and at risk for T1D as well as emerging technologies. It is expected that with systematic planning and execution of a well-conceived biomarker development pipeline, T-cell–related biomarkers would rapidly accelerate disease progression monitoring efforts and the evaluation of intervention therapies in T1D.

Type of Medium: Online Resource

ISSN: 0012-1797 , 1939-327X

URL: Article

DOI: 10.2337/db19-0119

Language: English

Publisher: American Diabetes Association

Publication Date: 2019

detail.hit.zdb_id: 1501252-9

Bookmarklink

Library	Location	Call Number	Volume/Issue/Year	Availability

Others were also interested in ...

Online Resource

Open Access Request

Availability (electronic / print)

Link to publisher

Online Resource

Sensitive detection of multiple islet autoantibodies in type 1 diabetes using small sample volumes by agglutination-PCR

Cortez, Felipe de Jesus ; Gebhart, David ; Robinson, Peter V. ; [et al.]

Public Library of Science (PLoS) ; 2020

In: PLOS ONE Vol. 15, No. 11 ( 2020-11-13), p. e0242049-

add to watchlist on the watchlist

Details

In: PLOS ONE, Public Library of Science (PLoS), Vol. 15, No. 11 ( 2020-11-13), p. e0242049-

Abstract: Islet autoantibodies are predominantly measured by radioassay to facilitate risk assessment and diagnosis of type 1 diabetes. However, the reliance on radioactive components, large sample volumes and limited throughput renders radioassay testing costly and challenging. We developed a multiplex analysis platform based on antibody detection by agglutination-PCR (ADAP) for the sample-sparing measurement of GAD, IA-2 and insulin autoantibodies/antibodies in 1 μL serum. The assay was developed and validated in 7 distinct cohorts (n = 858) with the majority of the cohorts blinded prior to analysis. Measurements from the ADAP assay were compared to radioassay to determine correlation, concordance, agreement, clinical sensitivity and specificity. The average overall agreement between ADAP and radioassay was above 91%. The average clinical sensitivity and specificity were 96% and 97%. In the IASP 2018 workshop, ADAP achieved the highest sensitivity of all assays tested at 95% specificity (AS95) rating for GAD and IA-2 autoantibodies and top-tier performance for insulin autoantibodies. Furthermore, ADAP correctly identified 95% high-risk individuals with two or more autoantibodies by radioassay amongst 39 relatives of T1D patients tested. In conclusion, the new ADAP assay can reliably detect the three cardinal islet autoantibodies/antibodies in 1μL serum with high sensitivity. This novel assay may improve pediatric testing compliance and facilitate easier community-wide screening for islet autoantibodies.

Type of Medium: Online Resource

ISSN: 1932-6203

URL: Article

DOI: 10.1371/journal.pone.0242049

DOI: 10.1371/journal.pone.0242049.g001

DOI: 10.1371/journal.pone.0242049.g002

DOI: 10.1371/journal.pone.0242049.g003

DOI: 10.1371/journal.pone.0242049.g004

DOI: 10.1371/journal.pone.0242049.t001

DOI: 10.1371/journal.pone.0242049.t002

DOI: 10.1371/journal.pone.0242049.t003

DOI: 10.1371/journal.pone.0242049.s001

DOI: 10.1371/journal.pone.0242049.s002

DOI: 10.1371/journal.pone.0242049.s003

DOI: 10.1371/journal.pone.0242049.s004

DOI: 10.1371/journal.pone.0242049.s005

DOI: 10.1371/journal.pone.0242049.s006

DOI: 10.1371/journal.pone.0242049.s007

DOI: 10.1371/journal.pone.0242049.s008

DOI: 10.1371/journal.pone.0242049.s009

DOI: 10.1371/journal.pone.0242049.s010

DOI: 10.1371/journal.pone.0242049.s011

Language: English

Publisher: Public Library of Science (PLoS)

Publication Date: 2020

detail.hit.zdb_id: 2267670-3

Bookmarklink

Library	Location	Call Number	Volume/Issue/Year	Availability

Others were also interested in ...

Online Resource

Open Access Request

Availability (electronic / print)

Link to publisher

hits 1 - 10 | 103 hits

Nothing or not found what you are looking for? Please check your search query or use the Interlibrary Loan Search.

Kooperativer Bibliotheksverbund

Berlin Brandenburg